RxDoctor Payments Data

Yamil Aude, MD

Cardiovascular Disease · McAllen, TXNPI 1942301619

Payments from drug & device makers

$71,580in general payments, 2019–2025

Across 33 payments — averaging $2169.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$46K
  • AstraZeneca$24K
  • Boston Scientific$391
  • Heartflow, Inc.$308
  • Johnson & Johnson$242
  • Abiomed$145
  • plus $333 from 4 others

What the payments were for

  • Consulting fees$16,00091%
  • Food & beverage$1,5699%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,580 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$128,488
Medicare patients
373
Services billed
1,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$253,472
XareltoRivaroxaban132$154,470
EntrestoSacubitril/Valsartan111$150,315
CamzyosMavacamten11$89,902
Ranolazine ErRanolazine117$12,356
VascepaIcosapent Ethyl18$8,649
Metoprolol Succinate460$6,330
Nifedipine ErNifedipine191$5,265
Isosorbide Dinitrate22$4,782
Hydralazine Hcl255$4,070
Rosuvastatin Calcium259$3,729
Atorvastatin Calcium349$3,301
Losartan Potassium328$3,263
Telmisartan73$2,665
Nebivolol Hcl29$2,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$242$154,470132 claims
E.r. Squibb & Sons, L.L.C.Camzyos$119$89,90211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →